All posts by imreal

Prevedere to Present Economic Outlook and Trends for CPG Industry at Path to Purchase Expo in Chicago


News Image

P2PX provides leaders in the consumer goods and retail industries with a roadmap to not only navigate change but be a catalyst for change. We look forward to demonstrating how the latest technologies combined with global data can help them do that.

Prevedere, the leader in predictive analytics software for economic intelligence, today announced it is a sponsor partner for the Path to Purchase Expo (P2PX) taking place November 13-14, 2019 in Chicago. The theme of the event this year is “A Bold Path Forward” with the agenda focusing on changing consumer behavior and how techniques such as insights, analytics, and new technologies can drive success in a consumer-centric market.

“Today’s marketplace is faced with disruption, due to changing economic conditions and consumer preferences, and we are finding more executives are looking for strategic insights to make data-driven decisions rather than relying on intuition,” said Rich Wagner, CEO of Prevedere. “P2PX provides leaders in the consumer goods and retail industries with a roadmap to not only navigate change but be a catalyst for change. We look forward to demonstrating how the latest technologies combined with global data can help them do that.”

Amid concerns of an economic slowdown in 2020, Prevedere’s will be presenting a thought leadership session, titled “Executive Insights: Ten Success-Driving Trends for 2020,” that will provide attendees with a better view of what to expect in the coming months and into next year. The session highlights key economic leading indicators for CPG companies to keep a close eye on. It also includes a special report from Coresight Research which identifies the top 10 US CPG trends such as digitization, premiumization, and private label.

“Our Path to Purchase/CGT readers and members are looking forward to having Prevedere be an important part of our member gathering at this year’s Path to Purchase Expo,” said Ed Several, Executive Vice President of Events for CGT-Path to Purchase Institute. “This year’s event will enable leaders to tame disruption and become the catalyst of change along the Path to Purchase. We see Prevedere playing a key role in the CGT community by offering their unique insights and predictive analytics capabilities to help business leaders make better decisions by providing a real-time view of their company’s future,” added Several.

For more information about the event: https://www.path2purchaseexpo.com/2019/session/193894/executive-insights-ten-success-driving-trends-for-2020

About Prevedere

Prevedere is a predictive analytics software company that delivers insights into future business outcomes based on economic trends. Our predictive economic intelligence offering helps executives see what lies ahead for their business and solve for upcoming risks and opportunities. Our SaaS solutions apply the power of machine learning and predictive modeling to millions of indicators of global economic and consumer activity. Prevedere customers include Fortune 500 industry leaders in retail, manufacturing, and consumer packaged goods. To learn more, visit http://www.prevedere.com and follow @Prevedere on Twitter.

Share article on social media or email:

Busch Center Opens State-of-the-Art Prostate Cancer Facility


“Busch Center’s team is making a positive difference for men who have prostate cancer.” Dr. Joseph J. Busch, MD

Prostate cancer is the second most common cancer among men, and the second leading cause of men’s cancer death in the United States.* That’s why Busch Center, a new state-of-the-art MRI prostate imaging facility, has opened in Alpharetta, GA. The experts at Busch Center pride themselves at detecting prostate cancer earlier and locating it more accurately than the current standard of care.

Busch Center, located at Brookside Concourse 100, 3650 Brookside Pkwy, Suite 175, has an innovative, non-invasive approach to detecting prostate cancer. Just like mammograms forever changed the outcomes for breast cancer through early detection and diagnosis in the 1970’s, Busch Center uses advanced imaging as part of a paradigm shift in prostate cancer detection.

“The key to successful cancer treatment is early detection,” says Dr. Joseph J. Busch, MD Oncological Radiologist. “The current guidelines in America over diagnose, under diagnose and miss an astonishing 30-40% of the cancer. We use the most advanced, least invasive technology available to properly screen men for prostate cancer and to accurately diagnose.”

Busch Center is the first private prostate center of excellence in the United States, combining precise imaging with personalized care. They offer MRI imaging, using the Siemens fourth-generation 3T imaging, to detect small prostate cancer lesions. Busch Center offers real-time imaging of the prostate while performing MRI Guided In-bore Targeted Biopsy with ADC Mapping, which is the most accurate biopsy method in the industry. Dr. Busch is a prostate imaging pioneer, who has been using the most sophisticated imaging for more than a decade. Every service and protocol at Busch Center are based on evidence-based medicine that is already the standard of care in Europe.

The “visible radiologist” present at the Busch Center is one of the things that sets them apart from other practices. Busch Center patients sit with the radiologist immediately following their scan to review their images and get their results while they’re in the office – no waiting and no worrying. The team provides personalized, compassionate care to every patient and their family.

“Busch Center’s team is making a positive difference for men who have prostate cancer,” says Dr. Busch, who also uses his imaging to determine patients’ response to therapies. “Where other medical teams use standard of care practices, Busch Center goes above and beyond to accurately evaluate responses to therapy to improve the quality of each patient’s life.”

About the Busch Center

Based in Atlanta, patients come to Busch Center from across the country and around the globe because of their high standards, personalized care, compassionate team, high-tech equipment, and state-of-the-art facilities. Busch Center’s team understands that every patient’s situation is different and – regardless of their specific circumstances – being diagnosed with prostate cancer is overwhelming and scary. Dr. Busch and his team talk to patients, answer their questions, review their scans, provide test results during the office visit, explain every procedure, and provide personalized recommendations for care plans based on evidence-based medicine.

Busch Center draws on the experience and methodologies used in Europe, where guidelines are different (and better) than they are in the US. Busch Center is setting a new (better) standard of care for prostate cancer screenings and treatments, and their patients experience better outcomes.

Connect with the Busch Center on Facebook/BuschCenter, Twitter/Busch Center, and Instagram/BuschCenter.

*Source: Cancer.net, Statistics adapted from the American Cancer Society’s (ACS) publication, Cancer Facts and Figures 2

Share article on social media or email:



Let’s Talk Interactive Platform and Civil Citation Network Demonstrate New Citation Software at 2nd Annual PTACC Conference


News Image

It’s our hope that our partnership with the Civil Citation Network will help keep more people away from the criminal justice system and result in increased public safety.

Let’s Talk Interactive, Inc., a leader in customizable Telehealth Networks and Solutions, today announces its technology will be featured in the 2nd Annual Police, Treatment, and Community Collaborative (PTACC) National Conference on Deflection and Pre-Arrest Diversion. The event, led by C4 Recovery Solutions, is held November 10-13, 2019 at the Sawgrass Marriott in Ponte Vedra, Florida.

The Civil Citation Network (CCN) has partnered with Let’s Talk Interactive (LTI) to incorporate its secure online software into its Adult Pre-Arrest Diversion Program (APAD). The program enables law enforcement officers issuing citations to incorporate evidence-based assessments and appropriate intervention services—with the goal of reducing recidivism. ‘“Intervening at the earliest point possible is critical,” said Tom Olk, Founder of CCN. “With over 10 million misdemeanor arrests on average each year, this problem will only get worse. Our case management solution, developed with LTI, links law enforcement, clinicians, and stakeholders together to effectively manage community diversion cases. If we help communities continue to protect public safety, hold individuals accountable for their actions, and reduce the economic burden of an arrest for their citizens, well then we’ve done our job.”

Kiosks and iPads will be on display at PTACC so attendees can walk through the APAD process for themselves. Telehealth and telemedicine carts that incorporate LTI’s technology will also be accessible, demonstrating how behavioral and physical health care is being brought directly to jails in rural areas with limited resources.

“Our mission is to provide unparalleled access to quality mental, acute and emergency healthcare to anyone who needs it. We are proud to support CCN in their efforts to divert people who have committed nonviolent misdemeanors towards appropriate treatment, which can be accessed via our online platform,” explained Art Cooksey, Founder of Let’s Talk Interactive. Inc. “It’s our hope that our partnership with CCN will help keep more people away from the criminal justice system and result in increased public safety.”

PTACC is the only conference centered around training, technical assistance, and information-sharing on pre-arrest diversion and deflection programs. These programs provide alternatives to justice system involvement for individuals with substance use and mental health disorders, as well as other offenders for whom diversion is a better solution.

For more information on PTACC, visit https://ptaccollaborative.org/. For more information on the Civil Citation Network, visit http://www.civilcitation.net.

About Let’s Talk Interactive, Inc.

Let’s Talk Interactive, Inc. is a complete end-to-end Telehealth solutions provider, arming medical and behavioral health professionals with cutting-edge Health Insurance Portability Accountability Act (HIPAA) video conferencing software, kiosks and medical carts, network solutions, virtual clinics, and safe and secure online video conferencing capabilities while giving those in need instant access to care through its innovative technology platform. The company’s telemedicine solutions enable providers to offer care at any time, from any location in the world and patients to directly connect to a licensed professional in real-time. For more information about Let’s Talk Interactive, visit https://letstalkinteractive.com.

Share article on social media or email:

Life Molecular Imaging and ITELPHARMA Announce a Strategic Partnership for Supply and Production of NeuraCeq in Puglia, Italy


News Image

Improved supply capabilities of NeuraCeq to meet increased demand in .

Life Molecular Imaging (LMI) and ITELPHARMA (ITEL) announced today that both companies have entered into a strategic partnership and licensing agreement providing ITEL with rights to manufacture and distribute NeuraCeq™ throughout the Italian regions of Puglia, Basilicata, Calabria and Campania.

Until recently these Italian regions were served by Curium Pharma Italy S.r.l. (Curium) that will retain distribution rights to supply NeuraCeq™ in the framework of the current public tenders won by them up to the expiry of these contracts. LMI would like to thank Curium for their efforts in the past and going forward to serve these customers for the duration of their respective contracts.

ITEL will start manufacturing NeuraCeq™ tracers in their radiopharmacy in Ruvo di Puglia as soon as the necessary authorizations are garnered from the applicable Italian authorities.

NeuraCeq™ is an approved imaging agent for the detection of beta-amyloid plaques in clinical routine. It is also a powerful imaging biomarker for the appropriate characterisation of subjects enrolled in clinical trials to support drug development in neurodegenerative diseases.

“Life Molecular Imaging continues to expand the availability of innovative molecular imaging agents and we are truly excited through this collaboration with ITEL to better serve physicians and our pharma partners with our approved NeuraCeq™ for clinical routine and research,” said Ludger Dinkelborg, Ph.D., Managing Director at LMI.

“We are very proud of this collaboration with Life Molecular Imaging,” declares Michele Diaferia, ITEL CEO. “This is an important goal in the process of increasing our company’s investments in the field of chemical-pharmaceutical activity in Italy. Our efforts in supporting competence, knowledge and research, materialize today in this strategic partnership. We are confident that, with our common activities in synergy with LMI, we will be able to give a strong scientific contribution to fight against diseases such as Alzheimer’s that still has a strong social impact.”

About NeuraCeq™ (florbetaben 18F)

Indication

NeuraCeq™ is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.

A negative NeuraCeq™ scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive NeuraCeq™ scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. NeuraCeq™ is an adjunct to other diagnostic evaluations.

Limitations of Use

  • A positive NeuraCeq™ scan does not establish the diagnosis of AD or any other cognitive disorder.
  • Safety and effectiveness of NeuraCeq™ have not been established for (i) predicting development of dementia or other neurologic conditions and (ii) monitoring responses to therapies.


Important Safety Information

Risk for Image Interpretation and Other Errors

NeuraCeq™ can be used to estimate the density of beta-amyloid neuritic plaque deposition in the brain. NeuraCeq™ is an adjunct to other diagnostic evaluations. NeuraCeq™ images should be interpreted independent of a patient’s clinical information. Physicians should receive training prior to interpretation of NeuraCeq™ images. Following training, image reading errors (especially false positives) may still occur. Additional interpretation errors may occur due to, but not limited to, motion artefacts or extensive brain atrophy.

Radiation Risk

Administration of NeuraCeq™, similar to other radiopharmaceuticals, contributes to a patient´s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. It is important to ensure safe handling to protect patients and health care workers from unintentional radiation exposure.

Most Common Adverse Reactions

In clinical trials, the most frequently observed adverse drug reactions in 1077 subjects with 1295 NeuraCeq™ administrations were injection/application site erythema (1.7%), and injection site pain (3.4%).

About Life Molecular Imaging (LMI)

Life Molecular Imaging (LMI, formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. It is now part of the Alliance Medical Group (a member of the Life Healthcare Group) offering an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. The organization strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.

Please visit https://life-mi.com.

About Life Healthcare Group

Life Healthcare Group is a market-leading, international, diversified healthcare organization. Life Healthcare has over 33 years’ experience in the South African private healthcare sector, and currently operates 66 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, and employee health and wellness services. The Group owns Alliance Medical Group, the leading independent provider of medical imaging services within Europe, operating across 10 international countries. Life Healthcare also owns Scanmed S.A. (Poland) which provides healthcare and medical services in 20 Polish cities, with over 65 medical specialisations and diagnostic services available in 32 facilities. Visit lifehealthcare.co.za

About ITEL

ITEL Telecomunicazioni Srl (also known as ITEL) is an Italian company established in 1982. It has three business sectors: 1) production of radiopharmaceuticals for PET diagnostics and supply of products and services for nuclear medicine, radioprotection and microbiology; 2) design and production of integrated technologies for diagnostics, nuclear medicine and advanced radiotherapy, including “turnkey” solutions; 3) an electromagnetic compatibility test laboratory, for CE marking of electrical and electronic products. In its Research & Development laboratory, ITEL is building an industrial prototype of a special linear proton accelerator, which, by means of a patented integrated system, ERHA, will be used to treat tumors with proton therapy. For more information please visit: http://www.itelte.it

For media queries

Nicole Fletcher | Marketing Communications | Life Molecular Imaging

Tel#: +1 857-202-1122 | n.fletcher@life-mi.com

Giovanni Grieco | Marketing Manager | ITEL

Tel#: +39 345 6558543 | g.grieco@itelte.it

Share article on social media or email:

ConnectiveRx, Upland Interfax and Scriptel Corporation successfully sponsored and exhibited at iPatientCare NUCON 2019, Cincinnati


ConnectiveRx, Upland Interfax and Scriptel Corporation exhibited at iPatientCare NUCON 2019

ConnectiveRx, Upland Interfax and Scriptel Corporation successfully sponsored and exhibited at iPatientCare NUCON 2019, Cincinnati

NUCON 2019 was the first conference I attended with iPatientCare. What I thought was really special is seeing how iPatientCare worked with their customers. Their customers are #1 & family to them. They spent a lot of time listening to what they are looking for & what will help in their routines.

iPatientCare, a pioneer in cloud-based EHR, Revenue Cycle Management services, integrated Practice Management and Patient Engagement solutions, welcomed ConnectiveRX as a Silver Sponsor, and Upland Interfax and Scriptel Corporation as the Bronze Sponsors at National User Conference (NUCON) 2019, held in Cincinnati, on October 18 – 19. The annual conference featured informative sessions about upcoming enhancements, user’s wish-lists based discussion sessions, hands-on demos with iPatientCare experts and exhibition showcased the leading-edge technologies.

As an integrated partner, ConnectiveRx provides clinical messaging support to iPatientCare users and helps them deliver clinical messages to prescribers seamlessly and in real-time within their EHR application based on actions they take in the workflow.

Upland Interfax’s cloud-based faxing capabilities embedded right into iPatientCare’s electronic medical record system provides the most secure methods of healthcare faxing to the end-users. Their cutting-edge desktop faxing services enables doctors and medical staff to send and receive faxes easily and cost-effectively.

Scriptel Corporation’s ScripTouch Signature Pads allow direct electronic capture of authentic handwritten signatures onto multiple consent forms at Check-In and within Patient Chart modules in the iPatientCare application. It lets users save time and cost, speed up patient interactions and reduces errors by going paperless with no signature pads related software to install or maintain.

During this two-day event, iPatientCare channel partners, certified professionals, business partners, end-users and healthcare experts from iPatientCare gathered to reflect on their evolution in the healthcare field, to celebrate accomplishments, to welcome new practitioners to their networks and to investigate what new directions the next ten years may bring.

“NUCON 2019 was the first conference I attended with iPatientCare. What I thought was really special is seeing how iPatientCare worked with their customers. Their customers are #1 and family to them. They spent a lot of time listening to what they are looking for and what will help in their day to day routines. As a partner, what is most important to me is my customers and how I can help make their day a bit easier by allowing them to focus on patients and not on other things and that is what is important to iPatientCare too,” said Randa Gallagher, Customer Relation and ISV Manager, Scriptel Corporation.

About iPatientCare

iPatientCare is a full suite of innovative healthcare products and value-added services that help physician offices, rural health clinics and community/federally qualified health centers (CHC/FQHC) nationwide in improving the health of their patients, enhancing patient care through care management/coordination/analytics and reducing costs of care delivery.

The awards-winning EHR, integrated practice solutions and value-added services, such as, the revenue cycle enhancement and quality improvement consulting, provide everything you need to control your practice operations, increase revenues and provide better patient care.

The iPatientCare EHR – version 18.0, has received 2015 Edition ONC Health IT certification by Drummond Group, an Office of the National Coordinator-Authorized Certification Body (ONC-ACB), in accordance with the applicable eligible professional certification criteria adopted by the Secretary of Health and Human Services (HHS). Full certification details can be found at the ONC Certified Health IT Product List.

As part of its MACRA-ready solutions, iPatientCare has been recognized as a qualified MACRA-MIPS registry by CMS, and has a distinguished credit of being selected as a preferred EHR and medical billing software by more than 70,000 users nationwide, numerous hospitals/health systems, federally funded regional extension centers and in the past by the US Army and NASA Space Medicine.

Visit http://www.iPatientCare.com for more information.

About ConnectiveRx

ConnectiveRx works with biopharmaceutical manufacturers to help commercialize and maximize the benefits of branded and specialty medications. They leverage industry-leading, tech-enabled services to accelerate speed to therapy throughout the medication journey. The unparalleled patient and provider network and advanced analytics power ConnectiveRx’s ability to improve medication adherence and access.

About Upland Interfax

The Interfax Internet Fax Service is a high-capacity, reliable and globally accessible service that enables transmission and reception of faxes from any internet connected application, with no installations. Upland’s enterprise work management cloud software enables every team in an organization to do their best work.

About Scriptel Corporation

Scriptel Corporation leads the way advancing reliable eSignature and signature capture technology. Their Citrix Ready, plug-and-play hardware and software solutions save time, cost and errors making it easy work of document signing, electronic record-keeping and practice management in the healthcare environment.

Scriptel (est. 1982) brought the first superior pen input on an LCD screen to market. Today they produce a full suite of ScripTouch® signature pads and workflow products. Scriptel is based in Columbus, Ohio, and has deployed more than 3 million products worldwide.

Share article on social media or email:

Content Pilot Hires Renowned Dallas Creative Director Michael Landon


Michael Landon

My design aesthetic completely aligns with Content Pilot’s – to solve business problems with design solutions in a brilliant and unforgettable way.

Strategic marketing and technology agency Content Pilot LLC has added Michael Landon to its award-winning design team. Stepping into the senior role of Design Director, Landon brings over three decades of experience working with some of the nation’s leading brands.

“My entire career has been focused on creating timeless brands and designs for my clients in multiple industries – from high-end product design and packaging to food and beverage, consumer products, health care professional services and non-profits,” Landon said. “Designing for professional services firms is refreshing because we’re tasked with designing energetic, memorable brands and websites in what are often traditionally-perceived industries. My design aesthetic completely aligns with Content Pilot’s – to solve business problems with design solutions in a brilliant and unforgettable way.”

Before joining Content Pilot, Landon designed for prominent law firms in Texas and across the U.S., as well as numerous top brands outside of professional services, including Anheuser-Busch, AT&T Byron Nelson Championship, Blue Cross Blue Shield, Capital One, Dr Pepper, ExxonMobil, Marriott, United Way, Xerox and more.

“I have worked with Michael for nearly 20 years as a trusted advisor and creative designer. I am thrilled we finally have him on our team,” Content Pilot CEO and Strategy Architect Deborah McMurray said. “Michael is a master collaborator and ally – clients love working with him.”

Content Pilot LLC is a full-service strategy, design, content and technology agency and a professional services industry leader. Founded in 2006, the company is headquartered in Dallas with 25 employees who collectively have more than 100 years of professional services experience. Content Pilot has achieved proven success by focusing on strategy first, then designing brands, award-winning websites, proposal automation systems and experience management solutions to many AmLaw 100-200 firms and other leaders throughout the United States and across the globe. The company also provides public relations and content marketing services. Learn more at http://www.contentpilot.com.

SOURCE: Content Pilot LLC

Like Content Pilot on Facebook

Follow Content Pilot on LinkedIn

Follow Content Pilot on Twitter

Follow Content Pilot on Instagram

Share article on social media or email:



Specialty MED Training Unveils New Physician Membership Program – Community of Like-Minded Physicians to Share, Learn and Grow in Regenerative Medicine


“Successful implementation into the clinical practice is by far the bigger challenge. We have taken the learning curve out of equation…” Joseph Banno, MD

Specialty Med Training, (SMT) one of the nation’s largest training, research and marketing companies, will unveil a brand new entry opportunity for practitioners into its national membership program at the 27th World Congress on Anti-Aging Medicine (A4M) in Las Vegas, NV on December 13-15, 2019.

Physicians are flocking to learn more about regenerative therapies, from Platelet Rich Plasma (PRP) and shockwave therapy to pharmaceutical peptides, stem cells, exosomes and all the benefits that the current science provides, not only for their patients, but for the health of their practice. To meet the growing need for continuing education and peer-to-peer collaboration, Specialty MED Training developed a community network of like-minded physicians conducting research and sharing ideas to advance the application of functional, regenerative, sexual and aesthetic medicine.

“For most physicians, learning the procedures is the easy part,” said Joseph Banno, MD. Chief Education Director for Specialty MED Training and board-certified urologist at Midwest Urology in Peoria Illinois. “Successful implementation into the clinical practice is by far the bigger challenge. We have taken the learning curve out of equation. Our network members receive a tremendous amount of support – from direct access to our board of clinical educators – to world class marketing programs that drive patients in the door.”

Specialty MED providers are leading the path towards evidence-based medicine and committed to educating practitioners on the science surrounding regenerative medicine – while promoting an ethical and responsible approach to new applications.

Membership Privileges include:


  • Physicians Fellowship- Collaboration Forum
  • Continuing Education- Monthly Educational Webinars
  • Opportunities to Participate in Research Studies
  • Ongoing Training Discounts
  • In-Service Clinical Support
  • Exclusive Access to Online Training Videos
  • Implementation Forms; Practice and Clinical
  • Clinical and Office Staff Training
  • Comprehensive Marketing-in-a-Box Tools
  • Fully Customizable Patient Marketing Collateral

To learn how you can become a member, visit specialtymedtraining.com or call 561-408-7248.

About Specialty Med Training

Specialty MED Training (SMT) is a national training, research and marketing company; dedicated to helping physicians bring the latest regenerative therapies and treatment options to their patients. They are actively building a national network of leading providers committed to the ethical and responsible advancement of the use of regenerative therapies in clinical practice.

Share article on social media or email:

Palma Ceia SemiDesign to Showcase Complete NB-IoT Solution during Synopsys ARC Processor Summit in Beijing, November 13, 2019


“The combination of the Synopsys ARC Processor IP with Palma Ceia’s RF transceiver makes it possible for designers to implement a complete, low-power NB-IoT solution – faster and with reduced cost and risk.” – Roy E. Jewell, CEO, Palma Ceia SemiDesign

Palma Ceia SemiDesign, a provider of next-generation wireless connectivity solutions, today announced it will exhibit at the Synopsys ARC® Processor Summit in Beijing on November 13 at the Shangri La Hotel. Palma Ceia SemiDesign will feature its NB IoT modem solution, built in collaboration with Synopsys.

“Our collaboration with Synopsys delivered a complete, integrated NB-IoT solution consisting of our RF Transceiver IP and Synopsys’ ARC EM9D processor,” said Roy E. Jewell, president and CEO of Palma Ceia SemiDesign. “The combination of the Synopsys ARC Processor IP with Palma Ceia’s RF transceiver makes it possible for designers to implement a complete, low-power NB-IoT solution – faster and with reduced cost and risk.”

The Synopsys ARC Processor Summit features presentations and demos from Synopsys experts, ARC users and ARC ecosystem partners. Attendees will learn about general electronic market trends as well as specific ARC-based solutions for a broad spectrum of embedded domains including IoT, automotive safety, embedded vision and security.

The NB-IoT modem solution includes the Palma Ceia silicon-proven RF transceiver along with Synopsys’ ultra-low power ARC EM9D processor, which combines RISC and DSP capabilities for a flexible architecture that can be quickly adapted for rapidly changing wireless standards. The EM9D’s zero-latency XY memory architecture takes advantage of instruction level parallelism and single-cycle 16+16 MAC operations to deliver power-efficient data processing.

For more information and to register for the ARC Summit see the Synopsys website: https://www.synopsys.com/designware-ip/processor-solutions/arc-processor-summit.html.

About Palma Ceia SemiDesign

Palma Ceia SemiDesign (PCS) is a leading provider of communication IP and semiconductors for next-generation WiFi and cellular applications. With a focus on emerging WiFi and LTE standards, PCS targets the design of ICs for broadband, wireless, medical and automotive applications. Palma Ceia solutions are differentiated by low-power, high-performance and ease of integration. With operational headquarters in Hong Kong, the company has its North American operations headquartered in Santa Clara, Calif. and original design center in McKinney, Texas. Additional sales and support activities are located in greater China, Israel, Japan, Korea, Taiwan and the United Kingdom. Visit Palma Ceia SemiDesign on the web at http://www.pcsemi.com.

Palma Ceia SemiDesign and the Palma Ceia SemiDesign logo are trademarks of Palma Ceia SemiDesign, Inc., and are protected by trademark laws of the United States and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective companies.

Share article on social media or email:

Autistic Boy Inspires Children’s Book Series


Our Family

Every story stems from something that has actually happened with a slight spin that is particular to Merlin

In his inaugural effort, author Frank Yeager has begun writing stories inspired by the unique way his son sees the world. Illustrated by Mr. Yeager’s childhood friend, Jude Rose Ickes of Scottdale, PA, it will be the first of multiple books featuring his son, currently an eight-year-old with high functioning Autism Spectrum Disorder and Attention Deficit Disorder.

Merlin’s Magic World is intended to be a series of books that will take their inspiration from people and events that Merlin has actually interacted with. The first book Merlin Meets the Man in the Moon, focuses on Merlin’s obsession with the moon and stars and takes him on an adventure. Published under the imprint LCI Media, readers can expect a new book about every three to four months. “Having a child later in life is blessing enough,” Frank says. “It is truly wonderful to be able to rediscover the world through his eyes.”

Frank Yeager is a veteran, inventor, entrepreneur, and now author. His accomplishments can be seen on his website, http://frankyeager.net. Merlin is his son and the accomplishment of which he is the most proud.

Jude Rose Ickes is an artist who studied illustration at the Art Institute of Pittsburgh. She currently resides in the small town of Scottdale, PA with her husband and two children where she works as a freelance artist specializing in graphite portraits and children’s book illustration.

Merlin Meets the Man in the Moon is available for $12.97 directly from the author’s website (http://www.frankyeager.net/books/) or on Amazon. Booksellers and libraries can order through Ingram Spark.

Share article on social media or email:

National Association of MLTSS Plans Welcomes Mary Kaschak as Executive Director


The Board of Directors of the National MLTSS Health Plan Association (MLTSS Association) is pleased to announce the appointment of Mary Kaschak to the position of Executive Director effective October 1, 2019.

The MLTSS Association is an organization comprised of the leading managed care organizations that deliver high-value, quality managed long-term services and supports (MLTSS) for state Medicaid programs and beneficiaries. Association members also contract jointly with state Medicaid agencies and the Centers for Medicare & Medicaid Services (CMS) to offer integrated Medicare-Medicaid Plans for individuals who have dual eligibility for both programs. The Association and its members are national leaders in promoting integrated care for dually-eligible beneficiaries as well as advancing high-quality (LTSS) and improving the collection and reporting of measures of the quality of care.

Mary has been serving as the Association’s Deputy Director and as the Executive Director of the Association’s affiliate – the Long-Term Quality Alliance (LTQA) – since January. She replaces Larry Atkins, who served as the Association’s Executive Director since its founding in September 2016. Larry will remain as Senior Advisor to the Association.

Mary came to the Association with over ten years of experience in aging and health policy, most recently as Deputy Director of the Aging and Disability Business Institute at National Association of Area Agencies on Aging (n4a). At the Business Institute, Mary played a lead role in advancing the readiness and business acumen of community-based organizations (CBOs) to successfully engage in the design and delivery of integrated care systems for older adults and younger adults with disabilities. In that capacity, she had extensive experience with the delivery of LTSS in general and with Medicaid MLTSS and integrated health plans in particular.

Board Chair Michael Monson and Vice Chair Christopher Palmieri welcome Mary as the new Executive Director for the Association. “Mary’s passion for the people who need these services, her commitment to advancing managed and integrated care, and her experience with LTSS are proving to be invaluable to the Association,” commented Monson.

The Board thanks Larry for the instrumental role he played in the creation and development of the Association and in remaining involved through this last year to ensure a smooth transition to new leadership.

The National MLTSS Health Plan Association is a non-profit association dedicated to: promoting the interests of plans that contract with state Medicaid programs to take risk for the cost of providing managed long-term services and supports (MLTSS) to Medicaid beneficiaries; advocating for public policy that will improve the quality and cost outcomes of MLTSS plans; and increasing public understanding of the benefits of MLTSS. Member organizations are: Aetna Inc., AmeriHealth Caritas, CareSource, Centene Corp., Commonwealth Care Alliance, Health Plan of San Mateo, L.A. Care Health Plan, Tufts Health Plan, UPMC Health Plan, VNSNY CHOICE, and WellCare Health Plans Inc.

For more information, visit http://www.mltss.org.

Share article on social media or email: